Sarepta Therapeutics (SRPT) Posts Smaller Q1 Loss, Revs Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments
May 6, 2020 4:05 PM EDTNet sales of $100.4 million, a 15% increase over same quarter of prior year
$2.2 billion of cash on hand to drive clinical programs without distraction from COVID-19 pandemic
CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three months ended March 31, 2020.
I am proud to report that with our typical sense of urgency the Sarepta team rapidly adapted to the challenges and obstacles posed by the... More
